Investors in biotech innovator Abviris Deutschland are injecting almost two million Euros to speed up expansion, after promising results for its immunoassay biomarker for the early diagnosis of cancers caused by human papillomavirus (HPV).
The Abviris biomarker incorporated into its CE-marked Prevo-Check point-of-care (POC) system focuses on HPV16, the most aggressive of all HPV strains and responsible for more than 90% of all HPV-related head and neck tumours, and for over half of cervical cancer cases. It relies on detecting an immune response that only occurs when HPV infection has triggered tumour growth. This is the first available blood-based test shown to be specific enough to aid in diagnosis
The company is already spearheading the development of further POC applications for the immunoassay technology, designed to address the clinical needs of other high-risk HPV types. Dr. Roman Niedbal, the company’s new CEO, explained: “Abviris is on the cusp of major expansion, with this pivotal study drawing immediate attention from potential partners and clinicians keen to collaborate.